Literature DB >> 34126047

Targeting RET-mutated thyroid and lung cancer in the personalised medicine era.

Joanna Klubo-Gwiezdzinska1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 34126047      PMCID： PMC9478888          DOI： 10.1016/S2213-8587(21)00152-2

Source DB:  PubMed          Journal:  Lancet Diabetes Endocrinol        ISSN： 2213-8587            Impact factor:   44.867


× No keyword cloud information.
  9 in total

Review 1.  Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma.

Authors:  Samuel A Wells; Sylvia L Asa; Henning Dralle; Rossella Elisei; Douglas B Evans; Robert F Gagel; Nancy Lee; Andreas Machens; Jeffrey F Moley; Furio Pacini; Friedhelm Raue; Karin Frank-Raue; Bruce Robinson; M Sara Rosenthal; Massimo Santoro; Martin Schlumberger; Manisha Shah; Steven G Waguespack
Journal:  Thyroid       Date:  2015-06       Impact factor: 6.568

Review 2.  RET revisited: expanding the oncogenic portfolio.

Authors:  Lois M Mulligan
Journal:  Nat Rev Cancer       Date:  2014-03       Impact factor: 60.716

Review 3.  2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer.

Authors:  Bryan R Haugen; Erik K Alexander; Keith C Bible; Gerard M Doherty; Susan J Mandel; Yuri E Nikiforov; Furio Pacini; Gregory W Randolph; Anna M Sawka; Martin Schlumberger; Kathryn G Schuff; Steven I Sherman; Julie Ann Sosa; David L Steward; R Michael Tuttle; Leonard Wartofsky
Journal:  Thyroid       Date:  2016-01       Impact factor: 6.568

4.  Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study.

Authors:  Justin F Gainor; Giuseppe Curigliano; Dong-Wan Kim; Dae Ho Lee; Benjamin Besse; Christina S Baik; Robert C Doebele; Philippe A Cassier; Gilberto Lopes; Daniel S W Tan; Elena Garralda; Luis G Paz-Ares; Byoung Chul Cho; Shirish M Gadgeel; Michael Thomas; Stephen V Liu; Matthew H Taylor; Aaron S Mansfield; Viola W Zhu; Corinne Clifford; Hui Zhang; Michael Palmer; Jennifer Green; Christopher D Turner; Vivek Subbiah
Journal:  Lancet Oncol       Date:  2021-06-09       Impact factor: 41.316

5.  Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study.

Authors:  Vivek Subbiah; Mimi I Hu; Lori J Wirth; Martin Schuler; Aaron S Mansfield; Giuseppe Curigliano; Marcia S Brose; Viola W Zhu; Sophie Leboulleux; Daniel W Bowles; Christina S Baik; Douglas Adkins; Bhumsuk Keam; Ignacio Matos; Elena Garralda; Justin F Gainor; Gilberto Lopes; Chia-Chi Lin; Yann Godbert; Debashis Sarker; Stephen G Miller; Corinne Clifford; Hui Zhang; Christopher D Turner; Matthew H Taylor
Journal:  Lancet Diabetes Endocrinol       Date:  2021-06-09       Impact factor: 32.069

6.  A phase 2 study of lenvatinib in patients with RET fusion-positive lung adenocarcinoma.

Authors:  Toyoaki Hida; Vamsidhar Velcheti; Karen L Reckamp; Hiroshi Nokihara; Pallavi Sachdev; Tomoki Kubota; Takuya Nakada; Corina E Dutcus; Min Ren; Tomohide Tamura
Journal:  Lung Cancer       Date:  2019-09-16       Impact factor: 5.705

Review 7.  Properties of FDA-approved small molecule protein kinase inhibitors: A 2021 update.

Authors:  Robert Roskoski
Journal:  Pharmacol Res       Date:  2021-01-26       Impact factor: 7.658

8.  Vandetanib in patients with previously treated RET-rearranged advanced non-small-cell lung cancer (LURET): an open-label, multicentre phase 2 trial.

Authors:  Kiyotaka Yoh; Takashi Seto; Miyako Satouchi; Makoto Nishio; Noboru Yamamoto; Haruyasu Murakami; Naoyuki Nogami; Shingo Matsumoto; Takashi Kohno; Koji Tsuta; Katsuya Tsuchihara; Genichiro Ishii; Shogo Nomura; Akihiro Sato; Atsushi Ohtsu; Yuichiro Ohe; Koichi Goto
Journal:  Lancet Respir Med       Date:  2016-11-04       Impact factor: 30.700

Review 9.  Chasing the Target: New Phenomena of Resistance to Novel Selective RET Inhibitors in Lung Cancer. Updated Evidence and Future Perspectives.

Authors:  Sara Fancelli; Enrico Caliman; Francesca Mazzoni; Marco Brugia; Francesca Castiglione; Luca Voltolini; Serena Pillozzi; Lorenzo Antonuzzo
Journal:  Cancers (Basel)       Date:  2021-03-04       Impact factor: 6.639
  9 in total
  1 in total

1.  Evaluation of the Clinical Utility of Genomic Profiling to Inform Selection of Clinical Trial Therapy in Salivary Gland Cancer.

Authors:  Samuel Rack; Laura Feeney; Brindley Hapuarachi; Helen Adderley; Laura Woodhouse; Guy Betts; George J Burghel; Kevin J Harrington; Robert Metcalf
Journal:  Cancers (Basel)       Date:  2022-02-23       Impact factor: 6.639
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.